Pfizer And Sangamo Start Phase III Study For Hemophilia A Gene Therapy
Giroctocogene Fitelparvovec Sustains Factor VIII Levels With No Bleeds
The move into Phase III for giroctocogene fitelparvovec comes on the heels of BioMarin's surprise setback when the FDA demanded more proof of durability of its rival hemophilia A gene therapy Roctavian.
